Christina Takke
Managing Partner @ V-Bio Ventures
Amsterdam, The Netherlands
Christina Takke is a Series A investor at V-Bio Ventures in Amsterdam focused on Biotechnology and Therapeutics. Christina holds a PhD in Developmental Biology, which she obtained under the supervision of Prof. Dr. Campos-Ortega at the Institute of Development Biology of the University of Cologne. As an undergraduate Christina studied Molecular Biology / Biochemistry at the Technical University of Darmstadt, Université de Bordeaux and at the InstitutNational de la Recherche Agronomique (INRA) Montpellier. After her studies, she gained experience in working with biotech startup companies at Bio-Gen-Tec-NRW in Cologne, Germany, a regional development organization for the biotechnology industry. She evaluated business proposals and assisted the young biotech companies in the fundraising process. Christina joined the ABN AMRO Capital Life Sciences team as an analyst in 2000. Following this assignment she became Principal before being promoted to Partner. At Forbion Christina is responsible for scouting and analysis of new investment opportunities as well as general deal execution. Christina currently serves on the supervisory boards of Forbion’s portfolio companies Amakem NV, arGEN-X BV, and Pieris AG. In recent years she served on the board of Bioceros, and she was closely involved with GlycArt AG as a Board Observer (sold to Roche in 2005).
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Christina Takke invests in
Stages Christina Takke invests in
Countries Christina Takke invests in
Investment Focus
Industry
- Biotechnology 3 (100%)
- Therapeutics 2 (67%)
- Medical 1 (33%)
- Health Care 1 (33%)
Country
- Belgium 2 (67%)
- The Netherlands 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Flindr Therapeutics
|
Immagene develops personalized cancer immunotherapies to fight multiple cancer type. | $21.4M / Series A / Apr 24, 2024 | |
Precirix
|
Developing radio-immunotherapeutic drugs for cancer patients. | $39.3M / Series A / Nov 15, 2018 | |
Amakem
|
Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique ‘Localized Drug Action' platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducingside effects. | $19.7M / Series A / Sep 06, 2011 |
Co-Investors
About V-Bio Ventures
V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.
V-Bio Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Shelley Margetson
Managing Partner
|
|||
Willem Broekaert
Managing Partner
|
|||
|
Christina Takke
Managing Partner
|
|||
Ward Capoen
Partner
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Christina Takke invest in?
Christina Takke invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series A stage. Most of the 3 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Christina Takke last invest?
The most recent investment recorded for Christina Takke closed in Apr 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
